Roche wins Japan approval for personalised cancer drug Rozlytrek
Rozlytrek aims to treat people with a rare genetic anomaly, called NTRK fusions, that drive growth in a range of tumours found…
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.